MedCity Influencers, Sponsored Post

Introducing pioneering regenerative medicine

Regenerative medicines and the latest regulatory issues surrounding them will be a hot topic for discussion at the DIA 2014 50th Annual Meeting. A session titled “Pioneering Regenerative Medicine: Trends in Regulations for New Therapy” will introduce the first clinical research of induced pluripotent stem (iPS) cell products in Japan.

This post is sponsored by DIA.

Regenerative medicines and the latest regulatory issues surrounding them will be a hot topic for discussion at the DIA 2014 50th Annual Meeting. This year’s Annual Meeting will be in San Diego from June 15 to 19 and will feature a session titled “Pioneering Regenerative Medicine: Trends in Regulations for New Therapy,” under the Nonclinical and Translational Development/Early Phase Clinical Development track.

The session, to be held on June 16 from 8:30-10:00 AM, will introduce the first clinical research of induced pluripotent stem (iPS) cell products in Japan and review the current regulatory status and governmental efforts surrounding regenerative medicine. Speakers will also identify issues in the application of the new technology and discuss possible solutions.

iPS cells hold great promise in the field of regenerative medicine because they can propagate indefinitely, as well as give rise to every other cell type in the body such as neurons, heart, pancreatic, and liver cells, and therefore represent a single source of cells that could be used to replace those lost to damage or disease. iPS cell technology was pioneered by Shinya Yamanaka of Kyoto, Japan, who was awarded the 2012 Nobel Peace Prize for the discovery alongside Sir John Gurdon.

The session will be chaired by Shinji Miyake, PhD, Professor of the Center for Clinical Research at Keio University School of Medicine in Japan.

The DIA 2014 50th Annual Meeting: Celebrate the Past – Invent the Future is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development, and life cycle management of medical products all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

This year’s event celebrates DIA’s 50th Anniversary and will feature 260+ educational offerings over 21 tracks, 450+ exhibiting companies, over 125 representatives from global regulatory agencies, and much more. The meeting provides participants with a valuable opportunity to network with professionals from around the world, share knowledge, and build new relationships.

Find out more about DIA 2014 50th Annual Meeting at www.diahome.org/DIA2014.


DIA

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.

Shares0
Shares0